Durvalumab

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`DRUG-DURVALUMAB`
Type	Drug
Aliases	ImfinziДурвалумаб
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-CHOLANGIOCARCINOMA` `DIS-HCC` `DIS-NSCLC` `DIS-SCLC`
Sources	`SRC-AASLD-HCC-2023` `SRC-NCCN-HCC-2025`

Drug Facts

Class	Anti-PD-L1 human IgG1 monoclonal antibody (ICI)
Mechanism	Blocks PD-L1. Combined with tremelimumab (anti-CTLA-4) as STRIDE regimen for 1L unresectable HCC (HIMALAYA).
Typical dosing	STRIDE (HCC): single priming dose tremelimumab 300 mg + durvalumab 1500 mg q4w until progression.
Ukraine registered	True
NSZU reimbursed	True
Ukraine last verified	2026-04-27

Warnings

irAE spectrum (pneumonitis, colitis, hepatitis, endocrinopathies)

Notes

STRIDE (single priming tremelimumab + durvalumab maintenance) preferred over previous T+D Q4W dosing. HIMALAYA: mOS 16.4 vs 13.8 mo sorafenib in unresectable HCC. Useful when bevacizumab contraindicated (high-risk varices, recent thromboembolic event). PACIFIC: durvalumab consolidation post-CRT in stage III unresectable NSCLC — mOS not reached vs 29.1 mo placebo, paradigm- defining. CASPIAN: durva + chemo extensive-stage SCLC. Baseline + serial TFTs, LFTs, creatinine, cortisol, troponin if cardiac history. Hospitalize and start IV methylprednisolone for G3-4 irAE. UA: registered; НСЗУ покриває PACIFIC-режим (NSCLC III нерезектабельна) та ext-SCLC. STRIDE-режим (з tremelimumab) — без UA НСЗУ.

Used By

Contraindications

CI-PEMBROLIZUMAB-AUTOIMMUNE - CI-PEMBROLIZUMAB-AUTOIMMUNE

Regimens

REG-DURVA-CONSOLIDATION-PACIFIC - Durvalumab consolidation post-CRT (NSCLC stage III unresectable)
REG-DURVA-CONSOLIDATION-SCLC - Durvalumab consolidation post-CRT (LS-SCLC)
REG-DURVA-GEM-CIS-CHOLANGIO - Durvalumab + gemcitabine + cisplatin (TOPAZ-1) — 1L advanced biliary tract cancer
REG-DURVA-TREME-STRIDE - Durvalumab + Tremelimumab (STRIDE)
REG-EP-DURVA-SCLC - Etoposide-platinum + durvalumab (extensive SCLC, 1L)